Inc Research Holdings, Inc. (INCR): Michael Gibertini , President Clinical Development of Inc Research Holdings, Inc. sold 213,966 shares on Jun 6, 2016. The Insider selling transaction was reported by the company on Jun 7, 2016 to the Securities and Exchange Commission. The shares were sold at $43.45 per share for a total value of $9,223,171.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 3, 2016, Robert W Breckon (director) sold 11,691 shares at $43.52 per share price.On Apr 19, 2016, James T. Ogle (director) sold 114,806 shares at $50.00 per share price.Also, On Apr 14, 2016, D. Jamie Macdonald (Chief Executive Officer) sold 94,675 shares at $48.00 per share price.On Apr 4, 2016, Michael Gibertini (President Clinical Development) sold 9,000 shares at $40.78 per share price.
Shares of INC Research Holdings Inc (INCR) ended Friday, Jun 3, 2016 session in red amid volatile trading. The shares closed down -0.43 points or -0.96% at $44.23 with 4,76,618 shares getting traded. Post opening the session at $44.42, the shares hit an intraday low of $43.98 and an intraday high of $44.85 and the price vacillated in this range throughout the day. The company has a market cap of $2,398 M and the number of outstanding shares has been calculated to be 5,42,21,660 shares. The 52-week high of INC Research Holdings Inc is $57.11 and the 52-week low is $34.19.
Company has been under the radar of several Street Analysts.INC Research Holdings Inc is Downgraded by Robert W. Baird to Neutral while Lowering the Price Target of the company shares to $ 51 from a previous price target of $55 . Earlier the firm had a rating of Outperform on the company shares. The Rating was issued on May 3, 2016.INC Research Holdings Inc is Initiated by JP Morgan to Overweight and the brokerage firm has set the Price Target at $47. The Rating was issued on Mar 24, 2016.
INC Research Holdings Inc. is a global contract research organization (CRO). The Company is focused on Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. The Company’s segment Clinical Development Services offers a variety of clinical development services including global studies clinical monitoring investigator recruitment patient recruitment data management and study reports. The Company’s segment Phase I Services focuses on clinical development services for Phase I trials that include scientific exploratory medicine first-in-human studies through proof-of-concept stages and support for Phase I studies in established compounds. The Company’s segment Global Consulting provides consulting services regarding clinical trial regulatory affairs regulatory consulting services quality assurance audits and pharmacovigilance consulting non-clinical consulting and medical writing consulting.